Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,706 GBX | +0.05% | +1.78% | +17.47% |
08:11am | GSK : Sell rating from JP Morgan | ZD |
02:17am | U.S. FDA approves Akebia's anemia drug | RE |
Sales 2024 * | 31.56B 39.82B | Sales 2025 * | 33.49B 42.26B | Capitalization | 69.67B 87.92B |
---|---|---|---|---|---|
Net income 2024 * | 5.6B 7.07B | Net income 2025 * | 6.25B 7.89B | EV / Sales 2024 * | 2.61 x |
Net Debt 2024 * | 12.57B 15.86B | Net Debt 2025 * | 9.37B 11.82B | EV / Sales 2025 * | 2.36 x |
P/E ratio 2024 * |
12.4
x | P/E ratio 2025 * |
11
x | Employees | 70,212 |
Yield 2024 * |
3.59% | Yield 2025 * |
3.87% | Free-Float | 92.08% |
Latest transcript on GSK plc
1 day | +0.18% | ||
1 week | +3.55% | ||
Current month | +2.44% | ||
1 month | +2.05% | ||
3 months | +17.63% | ||
6 months | +12.29% | ||
Current year | +17.58% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +7.01% | - | |
2.51% | 4 M€ | +9.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1,703 | -0.11% | 187 683 |
24-03-27 | 1,705 | +0.44% | 4,757,690 |
24-03-26 | 1,698 | +0.19% | 7,986,785 |
24-03-25 | 1,695 | +0.46% | 6,432,415 |
24-03-22 | 1,687 | +0.78% | 10,423,830 |
Delayed Quote London S.E., March 27, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.58% | 87.97B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.11% | 210B | |
+1.34% | 210B | |
-7.26% | 201B | |
-3.51% | 157B |